Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Disease sites
  • Pancreas
  • Pancreatic cancer

Pancreatic cancer

  • Charts and Tables

    Charts and Tables

    Figure 8.17

    Incidence and mortality rates for pancreatic cancer, by sex, Canada, age-standardized to the 2011 Canadian population — from 1992 to 2012

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    Data source: Statistics Canada, Canadian Cancer Registry and Vital Statistics Death Database.

    Data Table

    YearMeasureSexAge-standardized rate (per 100,000 population)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    1992IncidenceFemale11.410.812.0
    1992IncidenceMale15.114.316.0
    1993IncidenceFemale11.510.912.1
    1993IncidenceMale14.814.015.7
    1994IncidenceFemale11.911.312.5
    1994IncidenceMale14.713.915.5
    1995IncidenceFemale10.610.111.2
    1995IncidenceMale14.914.115.7
    1996IncidenceFemale11.310.811.9
    1996IncidenceMale14.113.314.9
    1997IncidenceFemale11.410.912.0
    1997IncidenceMale13.712.914.4
    1998IncidenceFemale11.410.812.0
    1998IncidenceMale14.313.615.1
    1999IncidenceFemale10.810.311.4
    1999IncidenceMale14.213.515.0
    2000IncidenceFemale11.210.611.7
    2000IncidenceMale14.513.815.2
    2001IncidenceFemale11.010.511.6
    2001IncidenceMale14.413.715.1
    2002IncidenceFemale11.310.711.8
    2002IncidenceMale13.612.914.3
    2003IncidenceFemale11.711.212.3
    2003IncidenceMale13.913.314.6
    2004IncidenceFemale11.511.012.1
    2004IncidenceMale14.313.614.9
    2005IncidenceFemale12.111.512.6
    2005IncidenceMale13.913.314.6
    2006IncidenceFemale11.010.511.5
    2006IncidenceMale13.512.914.2
    2007IncidenceFemale11.310.811.9
    2007IncidenceMale14.213.614.8
    2008IncidenceFemale11.210.711.7
    2008IncidenceMale13.613.014.2
    2009IncidenceFemale11.310.811.8
    2009IncidenceMale14.213.614.8
    2010IncidenceFemale10.29.810.7
    2010IncidenceMale12.511.913.0
    2011IncidenceFemale10.910.511.4
    2011IncidenceMale13.713.114.3
    2012IncidenceFemale11.210.711.6
    2012IncidenceMale13.513.014.1
    1992MortalityFemale10.910.311.5
    1992MortalityMale15.314.416.1
    1993MortalityFemale11.310.711.9
    1993MortalityMale15.014.215.9
    1994MortalityFemale11.410.812.0
    1994MortalityMale14.914.115.8
    1995MortalityFemale10.710.211.3
    1995MortalityMale14.613.815.4
    1996MortalityFemale11.310.711.9
    1996MortalityMale14.814.015.6
    1997MortalityFemale10.810.211.3
    1997MortalityMale13.612.914.4
    1998MortalityFemale11.010.411.6
    1998MortalityMale14.113.414.9
    1999MortalityFemale10.710.111.2
    1999MortalityMale14.413.715.2
    2000MortalityFemale10.810.311.4
    2000MortalityMale13.713.014.4
    2001MortalityFemale10.610.111.2
    2001MortalityMale14.113.414.9
    2002MortalityFemale10.710.111.2
    2002MortalityMale13.512.814.2
    2003MortalityFemale11.110.611.7
    2003MortalityMale14.113.414.8
    2004MortalityFemale11.310.811.8
    2004MortalityMale14.113.414.8
    2005MortalityFemale10.710.211.2
    2005MortalityMale13.312.714.0
    2006MortalityFemale10.910.411.5
    2006MortalityMale13.512.814.1
    2007MortalityFemale10.810.311.3
    2007MortalityMale14.013.414.6
    2008MortalityFemale10.710.211.2
    2008MortalityMale13.613.014.3
    2009MortalityFemale10.910.411.4
    2009MortalityMale13.813.214.4
    2010MortalityFemale10.49.910.9
    2010MortalityMale13.012.413.6
    2011MortalityFemale10.610.111.0
    2011MortalityMale13.512.914.1

    + Expand Table

    Data source: Statistics Canada, Canadian Cancer Registry and Vital Statistics Death Database.

    Figure 8.18

    Incidence rates for pancreatic cancer, by sex and province, age-standardized to the 2011 Canadian population — 2010–12 combined

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    Data source: Statistics Canada, Canadian Cancer Registry.

    Data Table

    ProvinceSexAge-standardized incidence rate (per 100,000 population)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    BCMale13.312.414.2
    BCFemale10.49.611.1
    ABMale13.512.414.7
    ABFemale12.311.313.3
    SKMale14.112.316.2
    SKFemale12.010.413.7
    MBMale17.115.119.3
    MBFemale12.310.813.9
    ONMale12.612.113.1
    ONFemale10.610.211.0
    QCMale14.013.314.7
    QCFemale10.710.111.2
    NBMale14.512.316.9
    NBFemale11.910.113.8
    NSMale13.711.815.8
    NSFemale12.110.513.9
    PEMale14.59.820.7
    PEFemale10.97.215.9
    NLMale11.08.813.7
    NLFemale9.37.411.5

    + Expand Table

    Data source: Statistics Canada, Canadian Cancer Registry.

    Figure 8.19

    Mortality rates for pancreatic cancer, by province, age-standardized to the 2011 Canadian population — 2009–11 combined

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    Data Source: Statistics Canada, Vital Statistics Death Database.

    Data Table

    ProvinceCases Age-standardized mortality rate (per 100,000 population)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    NL18011.29.613.0
    SK36011.310.212.6
    AB98511.410.712.2
    ON4,41511.511.211.9
    MB42011.710.612.9
    BC1,64011.911.312.4
    PE5511.99.015.6
    NS39012.511.313.8
    QC3,14012.612.213.1
    NB31512.811.414.3

    + Expand Table

    Data Source: Statistics Canada, Vital Statistics Death Database.

  • Data specifications

    Data specifications

    Age-standardized Incidence Rates

    Definition: The incidence rate that would have occurred if the age distribution in the population of interest was the same as that of the standard, where incidence rate is defined as the number of cases of cancer (malignant neoplasms) newly diagnosed during a year, per 100,000 people at risk

    Numerator: Number of new cancer cases (all ages):

    1. Breast (female)
    2. Colorectal
    3. Lung
    4. Prostate (male)
    5. Pancreas
    6. Ovary (female)

    Denominator: 1), 6): Annual female population estimate in hundreds of thousands; 2), 3), 5): Annual population estimates in hundreds of thousands 4: Annual male population estimate in hundreds of thousands

    Age standardization: Direct method using the 2011 Canadian Census population

    Data sources: Canadian Cancer Registry (CCR) Database – cancer incidence data; Demography Division of Statistics Canada – population estimates

    Measurement timeframe: For overall trends, Canada – 1992 to 2012. By province – 2010 to 2012 combined

    Stratification variables: Province, sex

    Notes:

    1. World Health Organization, International Classification of Diseases for Oncology, Third Edition (ICD- O-3) and the International Agency for Research on Cancer (IARC) rules for determining multiple primaries sites were used: colorectal (ICD-O-3: C18.0 to C18.9, C19.9, C20.9, C26.0), lung and bronchus (ICD-O-3: C34.0 to C34.9), female breast (ICD-O-3: C50.0 to C50.9), prostate (ICD-O-3: C61.9), pancreas (ICD-O-3: C25.0-C25.9), ovary (ICD-O-3: C56.9)
    2. Joinpoint Regression Program 4.2.0.2 for Windows was used to analyze linear trends across years. The software takes trend data and fits the simplest joinpoint model that the data allow. The program starts with the minimum number of joinpoints (e.g. 0 joinpoints, which is a straight line) and tests whether more joinpoints are statistically significant and must be added to the model (up to that maximum number). This enables the user to test whether an apparent change in trend is statistically significant. The tests of significance use a Monte Carlo Permutation method. Annual Percent Change (APC) was reported to characterize trends in cancer rates over time. APC assumes that cancer rates are changing at a constant percentage of the rate of the previous year. The minimum and maximum number of joinpoints used in this analysis were 0 and 4 respectively. For further details, refer to the Joinpoint Regression Program documentation (http://surveillance.cancer.gov/joinpoint/).

    Age-standardized Incidence Rates by Stage

    Definition: The stage-specific incidence rate that would have occurred if the age distribution in the population of interest was the same as that of the standard, where incidence rate is defined as the number of cases of cancer (malignant neoplasms) newly diagnosed during a specific time period, per 100,000 people at risk. Incidence rates by stage are available for five cancers: breast, lung, colorectal, prostate, and ovarian cancer

    Numerator: Number of new cancer cases for each stage during the given time period:

    1. Breast (female)
    2. Lung
    3. Colorectal
    4. Prostate (male)
    5. Ovary (female)

    Denominator: 1), 5): Population estimate per 100,000 women; 4): Population estimate per 100,000 men; 2), 3): Population estimate per 100,000 population

    Measurement timeframe: 2011 to 2013 combined

    Stratification variables: Province, stage at diagnosis (including stage I, II, III and IV)

    Data sources: Provincial cancer agencies

    Provinces submitting data: BC, AB, SK, MB, NB, NS, PE (breast, lung, colorectal, prostate); AB, SK, MB, NS, PE (ovarian)

    Age standardization: Direct method using the 2011 Canadian census population

    Province specific notes:

    • AB: Hematology, sarcoma and melanoma morphologies were removed from the site-specific cancers. All 2011-2013 invasive primaries are collaborative staging and once coded there should be no cases with missing/not available stage values. AB used AB’s 2012 population provided by Alberta Health Services (DIMR/Analytics) and the standardized 2011 Canadian population weights indicated on CPAC’s data specification document. For this indicator, 8002, 8073 and 8803 are included as NSCLC.
    • SK: SK-covered population estimates were used as the denominator in all standardized rates. NS: Lung (NSCLC + SCLC) also contains cases that could not be classified as either.

    Notes:

    1. World Health Organization, International Classification of Diseases for Oncology, Third Edition (ICD-O-3) and the International Agency for Research on Cancer (IARC) rules for determining multiple primaries sites were used: colorectal (ICD-O-3: C18.0, C18.2 to C18.9, C19.9, C20.9, C26.0), lung and bronchus (ICD-O-3: C34.0 to C34.9), breast (ICD-O-3: C50.0 to C50.9), prostate (ICD-O-3: C61.9).
    2. Appendix C18.1 was excluded from colorectal cancer.
    3. Sites with histology codes for lymphoma M-95 to M-98, sarcoma codes– 8800/3 were excluded.
    4. Cases for patients with age under 18 at diagnosis were excluded.
    5. American Joint Committee on Cancer 7 edition (AJCC 7) was used to classify cancer group stage.

    Age-standardized Mortality Rates

    Definition: The mortality rate that would have occurred if the age distribution in the population of interest was the same as that of the standard, where mortality rate is defined as the number of deaths due to cancer (malignant neoplasms) in a year per 100,000 people at risk

    Numerator: Number of deaths from cancer (all ages):

    1. Breast (female)
    2. Colorectal
    3. Lung
    4. Prostate (male)
    5. Pancreas
    6. Ovary (female)

    Denominator: 1), 6): Annual female population estimate in hundreds of thousands. 2), 3), 5): Annual population estimates in hundreds of thousands; 4): Annual male population estimate in hundreds of thousands

    Age standardization: Direct method using the 2011 Canadian Census population

    Data sources: Canadian Vital Statistics – Death Database – cancer mortality data; Demography Division of Statistics Canada – population estimates

    Measurement timeframe: For overall trends, Canada – 1992 to 2011. By province – 2009 to 2011 combined

    Stratification variables: Province

    Notes:

    1. Up to the year 1999, causes of death were coded according to World Health Organization (WHO), International Classification of Diseases, Ninth Revision (ICD-9): Colorectal (ICD-9 153-154), lung (ICD-9: 162), female breast (ICD-9: 174), prostate (ICD-9: 185), pancreas (ICD-9: 157), ovary (ICD-9: 183)
    2. After the year 1999, causes of death were coded according to the World Health Organization (WHO), International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10): Colorectal (ICD-10:C18-C20, C26.0), lung (ICD-10 : C34), female breast (ICD-10: C50), prostate (ICD-10: C61), pancreas (ICD-10: C25), ovary (ICD-10: C56.9)
    3. Joinpoint Regression Program 4.2.0.2 for Windows was used to analyze linear trends across years. The software takes trend data and fits the simplest joinpoint model that the data allow. The program starts with the minimum number of joinpoints (e.g. 0 joinpoints, which is a straight line) and tests whether more joinpoints are statistically significant and must be added to the model (up to that maximum number). This enables the user to test whether an apparent change in trend is statistically significant. The tests of significance use a Monte Carlo Permutation method. Annual Percent Change (APC) was reported to characterize trends in cancer rates over time. APC assumes that cancer rates are changing at a constant percentage of the rate of the previous year. The minimum and maximum number of joinpoints used in this analysis were 0 and 4 respectively. For further details, refer to the Joinpoint Regression Program documentation (http://surveillance.cancer.gov/joinpoint/).
  • Related indicators

    Related Indicators

    Smoking prevalence

    Percentage of Canadians ( aged >=12) who reported smoking daily or occasionally, Canada — from 2001 to 2015-16 reporting years
    View this indicator
    Smoking cessation

    Percentage of recent smokers (aged ≥ 20) reporting quitting smoking in the past two years, by age group and by sex, Canada — 2014 reporting year
    View this indicator
    Second-hand smoke exposure

    Percentage of non-smokers (aged ≥ 12) reporting second-hand smoke exposure, by setting and age group, Canada — 2014 reporting year
    View this indicator
    Adult overweight and obesity

    Adults classified as overweight or obese (%), by jurisdiction – 2015-16 years combined
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation